Federated Hermes Inc. Has $76.55 Million Holdings in Illumina, Inc. $ILMN

Federated Hermes Inc. trimmed its position in Illumina, Inc. (NASDAQ:ILMN) by 0.5% during the second quarter, HoldingsChannel.com reports. The firm owned 802,343 shares of the life sciences company’s stock after selling 4,416 shares during the quarter. Federated Hermes Inc.’s holdings in Illumina were worth $76,552,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Parkside Financial Bank & Trust raised its position in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after buying an additional 115 shares during the last quarter. Rise Advisors LLC grew its stake in shares of Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 224 shares in the last quarter. Cullen Frost Bankers Inc. acquired a new stake in shares of Illumina in the second quarter valued at approximately $41,000. NewSquare Capital LLC raised its holdings in shares of Illumina by 604.9% in the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after purchasing an additional 369 shares during the last quarter. Finally, Evelyn Partners Investment Management LLP lifted its position in shares of Illumina by 4,927.3% in the second quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock worth $49,000 after purchasing an additional 542 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Illumina news, Director Scott Gottlieb acquired 500 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was acquired at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the purchase, the director directly owned 12,523 shares of the company’s stock, valued at $1,529,433.99. This trade represents a 4.16% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.17% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on ILMN. Zacks Research raised shares of Illumina from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 2nd. Daiwa America cut Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 12th. UBS Group upped their target price on Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Daiwa Capital Markets downgraded Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price target for the company. in a research note on Tuesday, August 12th. Finally, TD Cowen boosted their price target on Illumina from $110.00 to $115.00 and gave the stock a “hold” rating in a research report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $115.00.

Illumina Price Performance

NASDAQ:ILMN opened at $128.96 on Monday. Illumina, Inc. has a one year low of $68.70 and a one year high of $153.06. The firm’s fifty day moving average price is $111.21 and its two-hundred day moving average price is $101.07. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The company has a market cap of $19.71 billion, a P/E ratio of 28.91, a P/E/G ratio of 2.31 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.18. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The firm’s revenue for the quarter was up .4% compared to the same quarter last year. During the same period last year, the firm posted $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.